Table 2.
Outcomes of interest
| Outcome of interest | Exposed, N=8,999 | Unexposed, N=24,118 |
|---|---|---|
| Incident outcomes after “start date”, n (%) | ||
| Non-skin cancer | 382 (4.2) | 947 (3.9) |
| Breast | 89 (1.0) | 219 (0.9) |
| Colon | 44 (0.5) | 99 (0.4) |
| Prostate | 39 (0.4) | 79 (0.3) |
| Lung | 58 (0.6) | 175 (0.7) |
| Other or nonspecific codesa | 152 (1.7) | 375 (1.6) |
| Hematological malignancy | 59 (0.6) | 139 (0.6) |
| Skin cancer | 270 (3.0) | 689 (2.8) |
| Metastasis | 59 (0.6) | 171 (0.7) |
| Death | 636 (7.1) | 1,665 (6.9) |
| Median time between “start date” and record of incident outcome (days) | ||
| Non-skin cancer | 1,159 (573–2,258) | 1,096 (623–1,786) |
| Hematological malignancy | 1,220 (670–2,229) | 971 (469–1,766) |
| Skin cancer | 1,061 (489–2,099) | 868 (436–1,585) |
| Metastasis | 1,399 (679–2,789) | 1,205 (811–1,815) |
| Death | 1,611 (918–2,518) | 1,461 (1,118–2,191) |
| Solid cancers diagnosed within 3 years before “start date”, n (%) | 149 (1.6) | 317 (1.3) |
| Breast | 42 (0.5) | 96 (0.4) |
| Colon | 9 (0.1) | 31 (0.1) |
| Prostate | 24 (0.3) | 35 (0.1) |
| Lung | 12 (0.1) | 15 (<0.1) |
| Skin cancer (excluding basal cell carcinoma) | 23 (0.2) | 53 (0.2) |
| Other or nonspecific codesa | 39 (0.4) | 87 (0.4) |
| Median time between cancers diagnosed within 3 years before “start date” and “start date” (days) | 535 (314–816) | 486 (224–781) |
Note:
a
For example, “adenocarcinoma”.